Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 5/20 | 0.39 |
| ▸ | QPCT | Q16769 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058825 | 0.97 | RAB9A (0.43) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058848 | 0.97 | RAB9A (0.43) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058747 | 0.97 | RAB9A (0.50) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058743 | 0.95 | RAB9A (0.49) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058741 | 0.95 | RAB9A (0.49) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058746 | 0.95 | RAB9A (0.49) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058758 | 0.95 | RAB9A (0.49) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058744 | 0.95 | RAB9A (0.49) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058768 | 0.95 | RAB9A (0.44) | RAB9AKDM4EMAPTLMNASUCNR1 | |
| SCHEMBL10058828 | 0.94 | RAB9A (0.48) | RAB9AKDM4EMAPTLMNASUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8480926-B2 | Liquid-crystalline compound and organic semiconductor device containing the compound | JNC CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8480926-B2 | Liquid-crystalline compound and organic semiconductor device containing the compound | JNC CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20120007062-A1 | NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND | JNC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120007062-A1 | NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND | JNC CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120007062-A1 | NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND | ARNT, SLCO2A1, CRY2 | RAB9A 1757/4885KDM4E 3424/4885MAPT 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.